|
Sep 27
|
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
|
|
Jan 4
|
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
|
|
Dec 19
|
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
|
|
Nov 2
|
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
|
|
Aug 27
|
Individual investors account for 43% of Knight Therapeutics Inc.'s (TSE:GUD) ownership, while private companies account for 22%
|